<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-0807</journal-id>
<journal-title><![CDATA[Revista de la Universidad Industrial de Santander. Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Univ. Ind. Santander. Salud]]></abbrev-journal-title>
<issn>0121-0807</issn>
<publisher>
<publisher-name><![CDATA[Universidad Industrial de Santander]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-08072017000300458</article-id>
<article-id pub-id-type="doi">10.18273/revsal.v49n3-2017004</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Concordancia de la utilización de teriparatide o ácido zoledrónico en pacientes con osteoporosis con recomendaciones internacionales, en una empresa de salud de Colombia]]></article-title>
<article-title xml:lang="en"><![CDATA[Concordance in the use of teriparatide or zoledronic acid in patients with osteoporosis with international recommendations, in a health company of Colombia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Henao Z]]></surname>
<given-names><![CDATA[Yuly]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Botero S]]></surname>
<given-names><![CDATA[Piedad L]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Parrado F]]></surname>
<given-names><![CDATA[Ilsa Y]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[Pedro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Tecnológica de Pereira  ]]></institution>
<addr-line><![CDATA[Pereira ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Antioquia  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universitat Pompeu Fabra  ]]></institution>
<addr-line><![CDATA[Barcelona ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2017</year>
</pub-date>
<volume>49</volume>
<numero>3</numero>
<fpage>458</fpage>
<lpage>468</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-08072017000300458&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-08072017000300458&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-08072017000300458&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  Los bifosfonatos son la primera línea de tratamiento para la osteoporosis; siendo el zolendronato el más efectivo. La teriparatide (agente anabólico), dado su alto costo, debería restringirse al tratamiento de pacientes más afectados y luego de un adecuado tratamiento con bifosfonatos.  Objetivo:  Establecer el porcentaje de pacientes con osteoporosis, en tratamiento con teriparatide o ácido zoledrónico en Colombia, que se ajusta a recomendaciones de organizaciones internacionales.  Método:  Estudio de utilización de medicamentos retrospectivo, enero 2012-diciembre 2015, en pacientes con osteoporosis y en tratamiento con teriparatide o ácido zoledrónico. Se revisó información sociodemográfica y clínica, y el grado de concordancia del uso de teriparatide o ácido zoledrónico con recomendaciones de tres guías clínicas internacionales: National Osteoporosis Foundation, National Institute for Health and Clinical Excellence y Scottish Intercollegiate Guidelines Network.  Resultados:  Se incluyeron 103 pacientes, edad promedio en años (desviación estándar) 78 (10,4), 74,8% mujeres. La osteoporosis posmenopáusica (61,2%) y osteoporosis no especificada (20,4%), ambas con o sin fractura patológica, fueron los diagnósticos principales. En el 36,9%, la utilización de teriparatide y ácido zoledrónico fue acorde a las recomendaciones de las guías revisadas. La utilización de estos medicamentos en diagnósticos diferentes a osteoporosis posmenopáusica (43,7%) o como farmacoterapia inicial (36,9%) fueron las principales causas para ausencia de concordancia.  Conclusiones:  Sólo en el 36,9% de los casos revisados, la utilización de teriparatide o ácido zoledrónico se ajusta a las guías de organizaciones internacionales. La ausencia de concordancia se debe, especialmente a uso en diagnósticos diferentes a osteoporosis posmenopáusica y como farmacoterapia inicial.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Bisphosphonates are the first-line treatment of osteoporosis in which zoledronate is the most effective. Teriparatide (anabolic agent), due to high cost, should be restricted to the treatment of the most affected patients and after adequate treatment with bisphosphonates.  Objective:  To establish the percentage of patients with osteoporosis, in treatment with teriparatide or zoledronic acid in Colombia, that meet international organizations recommendations.  Method:  Retrospective drug utilization study, January 2012-December 2015, in patients with osteoporosis and treatment with teriparatide or zoledronic acid. The socio-demographic and clinical information and the degree of concordance of teriparatide or zoledronic acid use with recommendations from three international clinical guidelines were reviewed: National Osteoporosis Foundation, National Institute for Health and Clinical Excellence, and Scottish Intercollegiate Guidelines Network.  Results:  103 patients were included, average age in years (standard deviation) 78 (10.4), 74.8% women. Postmenopausal osteoporosis (61.2%) and unspecified osteoporosis (20.4%), both with or without pathological fracture, were the main diagnoses. In 36.9%, the use of teriparatide and zoledronic acid was accord with the guidelines recommendations revised. The use of these drugs in diagnoses different to postmenopausal osteoporosis (43.7%) or initial pharmacotherapy (36.9%) were the main causes for concordance absence.  Conclusions: Only 36.9% of the reviewed cases, the use of teriparatide or zoledronic acid was accord with international organizations guideliness. Concordance absence is due especially both to the use in diagnoses different to postmenopausal osteoporosis and initial pharmacotherapy.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[osteoporosis]]></kwd>
<kwd lng="es"><![CDATA[teriparatide]]></kwd>
<kwd lng="es"><![CDATA[conservadores de la densidad ósea]]></kwd>
<kwd lng="es"><![CDATA[utilización de medicamentos]]></kwd>
<kwd lng="es"><![CDATA[farmacoepidemiología]]></kwd>
<kwd lng="en"><![CDATA[osteoporosis]]></kwd>
<kwd lng="en"><![CDATA[teriparatide]]></kwd>
<kwd lng="en"><![CDATA[bone density conservation agents]]></kwd>
<kwd lng="en"><![CDATA[drug utilization]]></kwd>
<kwd lng="en"><![CDATA[pharmacoepidemiology]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Migliore]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Broccoli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Massafra]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Cassol]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Frediani]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Rev Med Pharmacol Sci]]></source>
<year>2013</year>
<volume>17</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>658-67</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[World report on aging and health]]></source>
<year>2015</year>
<page-range>53-4</page-range><publisher-name><![CDATA[WHO Library cataloguing-inpublication Data]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zanchetta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[MacDonald]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[The Latin America Regional Audit Epidemiología, costos e impacto de la osteoporosis en 2012]]></source>
<year>2012</year>
<publisher-name><![CDATA[International Osteoporosis Foundation]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carmona]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Osteoporosis en Santafé de Bogotá]]></source>
<year>1999</year>
<publisher-name><![CDATA[Instituto Nacional de Salud de Colombia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Osteoporosis Committee of Pan-American League of Associations for Rheumatology The Burden of Osteoporosis in Latin America]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morales-Torres]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez-Ureña]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Osteoporos Int]]></source>
<year>2004</year>
<volume>15</volume>
<page-range>625-32</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Fracture Intervention Trial Research Group]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Cummings]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Karpf]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Cauley]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Nevitt]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>1996</year>
<volume>348</volume>
<numero>9041</numero>
<issue>9041</issue>
<page-range>1535-41</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Watts]]></surname>
<given-names><![CDATA[NB]]></given-names>
</name>
<name>
<surname><![CDATA[Genant]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Mckeever]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Hangartner]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Keller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[JAMA]]></source>
<year>1999</year>
<volume>282</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1344-52</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Oral Ibandronate Study Group Oral daily ibandronate prevents bone loss in ear ly postmenopausal women without osteoporosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[McClung]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Wasnich]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Recker]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cauley]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Chesnut 3rd]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Ensrud Ke]]></surname>
</name>
</person-group>
<source><![CDATA[J Bone Miner Res]]></source>
<year>2004</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1118</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Horizon Pivotal Fracture Trial Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Delmas]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Eastell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Reid]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
<name>
<surname><![CDATA[Boonen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cauley]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2007</year>
<volume>356</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1809-22</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lyles]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Colón-Emeric]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Magaziner]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Adachi]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Pieper]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HORIZON Recurrent Fracture Trial Zoledronic acid and clinical fractures and mortality after hip fracture]]></article-title>
<collab>Mautalen C et al</collab>
<source><![CDATA[N Engl J Med]]></source>
<year>2007</year>
<volume>357</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1799-809</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Menopause]]></source>
<year>2015</year>
<volume>22</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>10211025</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The cost-effectiveness of therapy with teriparitide and alendronate in women with severe osteoporosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Michaud]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nayak]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Karpf]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Owens]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Garber]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Intern Med]]></source>
<year>2006</year>
<volume>166</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1209-17</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Teriparatide vs. Alendronate as a treatment for osteoporosis: Changes in biochemical markers of bone turnover, BMD and quality of life]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Panico]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lupoli]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Marciello]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lupoli]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cacciapuoti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martinelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Med Sci Monit]]></source>
<year>2011</year>
<volume>17</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>442-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hodsman]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Dempster]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
<name>
<surname><![CDATA[Dian]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hanley]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Parathyroid hormone and teriparatide for the treatment of osteoporosis a review of the evidence and suggested guidelines for its use]]></article-title>
<collab>Harris ST et al</collab>
<source><![CDATA[Endocrine Rev]]></source>
<year>2005</year>
<volume>26</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>688-703</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Evaluación del manejo farmacológico de la osteoporosis y la osteopenia en una institución de régimen especial de Bogotá]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moncayo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev. salud pública]]></source>
<year>2015</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>565-77</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mayor]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Velandia]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Análisis de impacto presupuestal de teriparatide para reducir la frecuencia de fracturas vertebrales y no vertebrales, en adultos con riesgo elevado de fractura]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Bogotá-Colombia ]]></publisher-loc>
<publisher-name><![CDATA[Instituto de Evaluación Tecnológica en Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="">
<source><![CDATA[FRAX(r): The World Health Organization Fracture Risk Assessment Tool]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence of low femoral bone density in older U S. adults from NHANES III]]></article-title>
<collab>Looker AC1.Orwoll ES.Johnston CC Jr.Lindsay RL.Wahner HW.Dunn WL</collab>
<source><![CDATA[J Bone Miner Res]]></source>
<year>1997</year>
<volume>12</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1761-8</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="book">
<collab>National Osteoporosis Foundation</collab>
<source><![CDATA[Clinician's Guide to Prevention and Treatment of Osteoporosis]]></source>
<year>2010</year>
<publisher-loc><![CDATA[Washington ]]></publisher-loc>
<publisher-name><![CDATA[National Osteoporosis Foundation]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="book">
<collab>National Institute for Health and Clinical Excellence</collab>
<source><![CDATA[Osteoporosis: assessing the risk of fragility fracture]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Manchester ]]></publisher-loc>
<publisher-name><![CDATA[NICE guideline]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="book">
<collab>Scottish Intercollegiate Guidelines Network</collab>
<source><![CDATA[Management of osteoporosis and the prevention of fragility fractures]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Edinburgh ]]></publisher-loc>
<publisher-name><![CDATA[SIGN]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="book">
<collab>Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA)</collab>
<source><![CDATA[Registro sanitario: Teriparatide]]></source>
<year>2015</year>
<publisher-name><![CDATA[Colombia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="">
<collab>Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA)</collab>
<source><![CDATA[Registro sanitario: Ácido Zoledrónico 5 mg]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epidemiología de la osteoporosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vásquez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Colomb Reumatol]]></source>
<year>2009</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>61-75</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Current and future treatments of osteoporosis in men]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaufman]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Lapauw]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Goemaere]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Best Pract Res Clin Endocrinol Metab]]></source>
<year>2014</year>
<volume>28</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>871-84</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Reid]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
<name>
<surname><![CDATA[Boonen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bucci-Rechtweg]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cauley]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Cosman]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[J Bone Miner Res]]></source>
<year>2012</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>243-54</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Consumidores, prescripción y prescriptores de fármacos para la osteoporosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Idarreta]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Rua]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hernando]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zabaleta]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Arzuaga]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Irizar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[ACMB]]></source>
<year>2010</year>
<volume>107</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>90-6</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Patrones de prescripción de broncodilatadores y corticoides inhalados en pacientes adultos de Colombia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bañol]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Acta Med Colomb]]></source>
<year>2015</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>218-26</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
